Evolus (EOLS) Revenue & Revenue Breakdown
Evolus Revenue Highlights
Latest Revenue (Y)
$264.31M
Latest Revenue (Q)
$60.16M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Evolus Revenue by Period
Evolus Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $264.31M | 30.79% |
| 2023-12-31 | $202.09M | 35.98% |
| 2022-12-31 | $148.62M | 49.10% |
| 2021-12-31 | $99.67M | 76.29% |
| 2020-12-31 | $56.54M | 61.89% |
| 2019-12-31 | $34.92M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | - |
Evolus generated $264.31M in revenue during NA 2024, up 30.79% compared to the previous quarter, and up 756.78% compared to the same period a year ago.
Evolus Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $60.16M | -10.08% |
| 2024-06-30 | $66.91M | 12.77% |
| 2024-03-31 | $59.33M | -2.73% |
| 2023-12-31 | $61.00M | 23.67% |
| 2023-09-30 | $49.32M | -0.05% |
| 2023-06-30 | $49.35M | 18.28% |
| 2023-03-31 | $41.72M | -4.41% |
| 2022-12-31 | $43.65M | 28.75% |
| 2022-09-30 | $33.90M | -8.78% |
| 2022-06-30 | $37.16M | 9.60% |
| 2022-03-31 | $33.91M | -2.16% |
| 2021-12-31 | $34.66M | 29.91% |
| 2021-09-30 | $26.68M | 2.22% |
| 2021-06-30 | $26.10M | 113.20% |
| 2021-03-31 | $12.24M | -40.51% |
| 2020-12-31 | $20.58M | 16.51% |
| 2020-09-30 | $17.66M | 126.25% |
| 2020-06-30 | $7.81M | -25.63% |
| 2020-03-31 | $10.50M | -46.03% |
| 2019-12-31 | $19.45M | 47.69% |
| 2019-09-30 | $13.17M | 469.75% |
| 2019-06-30 | $2.31M | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | - |
Evolus generated $60.16M in revenue during Q3 2024, up -10.08% compared to the previous quarter, and up 121.92% compared to the same period a year ago.
Evolus Revenue Breakdown
Evolus Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Service | $1.97M | $2.36M | $2.02M | - | - |
| Product | $264.31M | $199.72M | $146.59M | $98.97M | $55.80M |
Evolus's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (99.26%), and Service (0.74%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | - | $921.00K | $687.00K | $369.00K | $328.00K | $696.00K | $666.00K | $674.00K | $658.00K | $684.00K | - | - | - | - | - | - | - |
| Product | $78.96M | $60.16M | $66.22M | $58.96M | $60.67M | $49.32M | $48.68M | $41.05M | $42.99M | $33.22M | $37.16M | $33.23M | $34.66M | $26.68M | $25.40M | $20.58M | $16.92M |
Evolus's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Evolus Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 21 | Dec 20 |
|---|---|---|---|
| UNITED STATES | $253.16M | - | - |
| Non-US | $13.12M | - | - |
| CANADA | - | $702.00K | $738.00K |
Evolus's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (95.07%), and Non-US (4.93%).
Quarterly Revenue by Country
| Country | Mar 22 | Jun 21 | Sep 20 |
|---|---|---|---|
| CANADA | $682.00K | $702.00K | $738.00K |
Evolus's latest quarterly revenue breakdown by geography, as of Mar 22: CANADA (100.00%).
Evolus Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALKS | Alkermes | $1.56B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $290.32M |
| PAHC | Phibro Animal Health | $977.89M | $309.26M |
| AMPH | Amphastar Pharmaceuticals | $712.81M | $188.82M |
| PCRX | Pacira BioSciences | $700.97M | $168.57M |
| ITCI | Intra-Cellular Therapies | $680.85M | $175.38M |
| SUPN | Supernus Pharmaceuticals | $661.82M | $175.69M |
| COLL | Collegium Pharmaceutical | $631.45M | $159.30M |
| ANIP | ANI Pharmaceuticals | $614.38M | $148.33M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EOLS | Evolus | $264.31M | $60.16M |
| IXHL | Incannex Healthcare | - | - |